Loading organizations...
§ Private Profile · Changping, Beijing, China
Biopharmaceutical company researching, developing, and commercializing T-cell immunotherapy for cancer treatment, focused on EAL.
Beijing-based China Immunotech, also known as Immunotech Biopharm Ltd, is a biopharmaceutical company focused on the research, development, and commercialization of T-cell immunotherapies for advanced cancer treatment. The organization centers its clinical oncology pipeline around EAL, a multi-target cellular immunotherapy designed to treat patients with solid tumors, which has undergone continuous clinical research and refinement since 2006. Operating as a publicly traded entity, the firm successfully completed its initial public offering on the Hong Kong Stock Exchange under the equity ticker 6978 in July 2020. The company utilizes proprietary cell production platforms with independent intellectual property rights, and is guided by executive leadership that includes Chief Executive Officer Jian Zhang and Chief Scientific Officer Jung Hyun Chul. China Immunotech was officially incorporated in Beijing in April 2018 by founder Yu Wang and Chairman Zheng Tan.
China Immunotech has raised $31.0M across 1 funding round.
China Immunotech has raised $31.0M in total across 1 funding round.
China Immunotech has raised $31.0M in total across 1 funding round.
China Immunotech's investors include China Growth Capital, Beijing Changping Science Park Development, Fenghai Capital, Guangzhou Sanheyue, Sangel Capital, Start Point Advisors, Jianwei YUAN.
China Immunotech has raised $31.0M across 1 funding round. Most recently, it raised $31.0M Series B in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 11, 2021 | $31M Series B | China Growth Capital | Beijing Changping Science Park Development, Fenghai Capital, Guangzhou Sanheyue, Sangel Capital, Start Point Advisors, Jianwei YUAN | Announced |